Elevated plasma levels of PAI-1 predict cardiovascular events and cardiovascular mortality in prevalent peritoneal dialysis patients

Renal Failure

Volumn 31, Issue 6, 2009, Pages 438-445

  Arikan, Hakki ^a   Koc, Mehmet ^a   Tuglular, Serhan ^a   Ozener, Cetin ^a   Akoglu, Emel ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cardiovascular outcome; PAI 1; Peritoneal dialysis

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; MALE; MORTALITY; PERITONEAL DIALYSIS; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 72649097143     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220902963772     Document Type: Article

References (40)

1. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49:1428-1434. (Pubitemid 26166417)
2. London GM, Marchais SJ, Metivier F, Guerin AP. Cardiovascular risk in end-stage renal disease: Vascular aspects. Nephrol Dial Transplant. 2000;15(Suppl. 5):97-104. (Pubitemid 30784398)
3. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
4. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
5. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003;108:391-394.
6. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.
7. Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E. Associations between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Ren Fail. 2007;29(6):713-719.
8. Lin JJ, Parton L, Bereket G, Wadhwa NK. Plasminogen activator inhibitor-1 and peritoneal transport in diabetic and non-diabetic peritoneal dialysis patients. Clin Nephrol. 1995;44:310-315.
9. Opatmy K Jr, Opatma S, Vit L, Opatmy K. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis. Am J Nephrol. 1998;18:186-192.
10. Tomura S, Nakamura Y, Doi M, et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis. 1996;27:848-854.
11. Rose GA, Blackburn H. Cardiovascular survey methods. Monogr Ser World Health Organ. 1968;56:1-188.
12. Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S. The electrocardiogram in population studies. A classification system. Circulation. 1960;21:1160-1175.
13. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ. 1962;27:645-658.
14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
15. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference interval and epidemiological applications. Clin Chem. 1997;43:52-58.
16. Goraya TY, Jacobsen SJ, Belau PG, Weston SA, Kottke TE, Roger VL. Validation of death certificate diagnosis of out-of-hospital coronary heart disease deaths in Olmsted County, Minnesota. Mayo Clin Proc. 2000;75:681-687.
17. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
18. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005;16 (Suppl. 1):83-88.
19. Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif. 2003;21:29-36.
20. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001. Thromb Res. 2001;103 (Suppl. 1):7-19.
21. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Hemost. 2005;3:1879-1883.
22. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 1996;94:2057-2063 .
23. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241-2247.
24. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med. 1986;163:1260-1266.
25. Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem. 264:10396-10401.
26. Goldstein SL, Leung JC, Silverstein DM. Pro- and antiinflammatory cytokines in chronic pediatric dialysis patients: Effect of aspirin. Clin J Am Soc Nephrol. 2006;1:979-986.
27. Segarra A, Chacón P, Martinez-Eyarre C, et al. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 2001;12:1255-1263.
28. Güz G, Nurhan Ozdemir F, Sezer S, et al. Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis. 2000;36:826-836.
29. Kunz K, Petitjean P, Lisri M, et al. Cardiovascular morbidity and endothelial dysfunction in chronic hemodialysis patients: Is homocyst(e)ine the missing link? Nephrol Dial Transplant. 1999;14:1934-1942.
30. Locatelli F, Andrulli S, Memoli B, et al. Nutritionalinflammation status and resistance to erythropoietin therapy in hemodialysis patients. Nephrol Dial Transplant. 2006;21:991-998.
31. Pawlak K, Pawlak D, Mysliwiec M. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients. Am J Nephrol. 2007;27:221-225. (Pubitemid 47164669)
32. Borawski J, Mysliwiec M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin Appl Thromb Hemost. 2002;8:77-84.
33. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
34. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Hemost. 1997;78:656-660.
35. Johnson DW, Herzig KA, Purdie DM, et al. Is obesity a favorable prognostic factor in peritoneal dialysis patients? Perit Dial Int. 2000;20:715-721.
36. Aslam N, Bernardini J, Fried L, Piraino B. Large body mass index does not predict short-term survival in peritoneal dialysis patients. Perit Dial Int. 2002;22:191-196.
37. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol. 2003;14:2894-2901.
38. Axelsson J, Rashid Qureshi A, Suliman ME, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr. 2004;80:1222-1229.
39. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002;62:1417-1422.
40. Lo WK. Serum parameters, inflammation, renal function and patient outcome. Contrib Nephrol. 2006;150:152-155.